Exclusive Summary

• Possesses EU-EMA GMP certification and BP/EP compliant API, overcoming the high regulatory barriers of low molecular weight heparins to enable rapid entry into European and PIC/S markets.
• Covers massive therapeutic demands, including over 10 million annual VTE cases and 3.4 million hemodialysis patients globally, serving as a first-line anticoagulant explicitly recommended by major guidelines.
• The originator patent has expired, but the complex drug nature results in fewer high-quality global generic competitors, avoiding severe homogeneous price wars.
• Available in mainstream pre-filled syringe dosages (0.4ml/0.6ml), highly ready for use and perfectly suited for immediate global Distribution partnerships.
• Leverages China's vertically integrated heparin supply chain to ensure stable supply and significantly lower costs compared to the originator (Fraxiparine), securing high margins for distributors.